Endocrinology

Weight loss and disease remission in T2D may differ between patients regardless of type of diet regimen chosen, say authors of a new analysis.

Among patients with diabetes, over 50% of statin users experienced diabetes progression vs 48% of non-statin users, according to a retrospective matched-cohort study.

EASD 2021: First analysis of its kind found COVID-19-induced lockdown was associated with improved glycemic control among patients with T1D, but not T2D.

From 2001 to 2017, the estimated prevalence of youth-onset T1D and T2D increased approximately 45% and 95%, respectively, according to a new study.

Low-income patients with diabetes enrolled in high-deductible health plans used less preventive and primary care services and more emergency visits, suggests new review.

Take this quick quiz to test your knowledge of key findings in landmark studies on the cardioprotective effects of SGLT2i and GLP-1 RAs.

These concise summaries highlight the latest findings on the cardioprotective effects of SGLT2 inhibitors and GLP-1 RA in patients with diabetes.

Five years after bariatric surgery for uncontrolled T2D patients reported improvements in physical health and QoL but measures of psychosocial wellbeing remained flat.

Early attainment of an A1c level below 7% was predictive of long-term glycemic control in patients with type 2 diabetes starting second-line glucose-lowering therapy in a new analysis.

A recent study found that the use of statins in patients with newly diagnosed T2D reduced incidence of cardiovascular disease and death, particularly among older patients.

ADA 2021. A subgroup analysis of the FIDELIO-DKD trial showed that finerenone use was beneficial regardless of baseline insulin use among patients with T2D and CKD.

ADA 2021. Dapagliflozin was found to reduce type 2 diabetes incidence among patients with chronic kidney disease in a prespecified analysis of the DAPA-CKD trial.

Data released today at the American Diabetes Association 81st Scientific Sessions on a spike in new onset pediatric T2D at a single center during COVID-19 may signal much wider incidence.

The upcoming ADA virtual 81st Scientific Sessions will feature 5 sessions on the latest diabetes developments learned during the initial phases of the COVID-19 pandemic.

The novel Bigfoot Unity Diabetes Management System could help improve insulin dosing in patients with type 1 or type 2 diabetes.

Assessment of prediabetes subphenotypes is a novel approach to better screening, prevention, and treatment for patients at risk of progression to T2D. Find out how much you know about it.

MOBILE study group: in patients with type 2 diabetes on a less intensive insulin regimen, CGM use lowered A1c and increased time in target glucose range vs traditional blood glucose monitoring.

Authors of a new study say their findings suggest bariatric surgery should be considered first-line treatment for the management of obesity in patients with type 2 diabetes.

New findings suggest that patients with asthma and type 2 diabetes who use GLP-1 RAs for diabetes treatment intensification have fewer asthma exacerbations compared to other diabetes drugs.

A recent study showed lifestyle counseling in primary care was effective in preventing type 2 diabetes in long-term follow-up.

In individuals with chronic coronary disease, the presence of diabetes increased the rate of death by 38% during a 5-year follow-up period in analysis of a worldwide patient registry.

ENDO 2021: A meta-analysis found increased cardiometabolic risk among Black women with PCOS vs White counterparts even though fasting glucose levels were comparable and triglyceride levels lower.

A lifestyle intervention targeting women with obesity and infertility is more effective in increasing the pregnancy rate vs fertility treatments, suggests a new study presented at ENDO 2021.

COVID-19 patients with hyperglycemia on hospital admission, with and without diabetes, had increased odds of intubation, ICU admission, and mortality, according to research presented at ENDO 2021.

ENDO 2021: An investigational once-weekly insulin formulation was found as effective as daily basal insulin injection for glucose control with lower rates of hypoglycemia and less weight gain.

Using metabolomic profiling from more than 11 000 individuals, researchers identified common pathways linking seemingly unrelated diseases that often co-occur.

Results from a head-to-head study show the investigational medication, tirzepatide, led to superior A1c and body weight reductions compared to semaglutide.

More than half of adults with obesity who received once-weekly semaglutide lost 15% of body weight, according to the recently published STEP 1 study.

A new review of >60 000 patients with diabetes found CGM use during the early weeks of the COVID-19 pandemic improved their time in range.

New research suggests obesity is responsible for 30%-53% of new type 2 diabetes cases in the US annually.